Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has announced that it is terminating the Phase III development program for its investigational compound, CP-945,598, for weight management. CP-945,598 is a selective antagonist of the cannabinoid type 1 receptor.
Subscribe to our email newsletter
Based on all currently available information and an ongoing review of the Phase III program by an independent data monitoring committee, Pfizer believes that the CP-945,598 compound has the potential to be a safe and effective treatment for weight management.
However, the company has decided to discontinue the development program based on changing regulatory perspectives on the risk/benefit profile of the cannabinoid type 1 class and likely new regulatory requirements for approval.
Martin Mackay, president of global R&D at Pfizer, said: “While confident in the safety of the compound, we believe that this is the appropriate decision based on all available information regarding this class of agents, as well as recent discussions with regulatory authorities.
“As part of our ongoing portfolio prioritization, we will refocus R&D resources on high priority therapeutic areas that address an unmet medical need and have a high probability for success.”